Biochemical and structural characteristics of crizotinib-resistant ALK mutants.

被引:0
作者
Timofeevski, Sergei [1 ]
Liu, Wei [1 ]
Deng, Ya-Li [1 ]
Brooun, Alex [1 ]
Bergqvist, Simon [1 ]
Karlicek, Shannon [1 ]
Murray, Brion [1 ]
Bolanos, Ben [1 ]
McTigue, Michele [1 ]
机构
[1] Pfizer Inc, San Diego, CA USA
关键词
D O I
10.1158/1538-7445.AM2013-4456
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
4456
引用
收藏
页数:1
相关论文
共 50 条
  • [21] TSR-011: A potent inhibitor of ALK with activity in crizotinib-resistant tumor models in phase 1-2 development for ALK plus NSCLC
    Weiss, G.
    Sachdev, J. C.
    Infante, J. R.
    Mita, M.
    Wilcoxen, K. M.
    Kansra, V.
    Brooks, D. G.
    Martell, R. E.
    Anthony, S. P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S831 - S831
  • [22] Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
    Rao, Chuangzhou
    Nie, Liangqin
    Wu, Xiaokang
    Miao, Xiaobo
    Chen, Ting
    Chen, Liuxi
    Zhang, Dongqing
    Lin, Quan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Morcos, Peter N.
    Nueesch, Eveline
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy C.
    Bordogna, Walter
    Balas, Bogdana
    Mercier, Francois
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
  • [24] Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R
    Wang, Yu
    Chen, Shaowei
    Hu, Gang
    Wang, Jiao
    Gou, Wenfeng
    Zuo, Daiying
    Gu, Yucheng
    Gong, Ping
    Zhai, Xin
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 143 : 123 - 136
  • [25] Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma
    Hidehiko Kuribayashi
    Shinji Abe
    Naoyuki Kuse
    Yuji Kusunoki
    Ritsuko Narato
    Hitoshi Saito
    Akihiko Gemma
    [J]. International Cancer Conference Journal, 2016, 5 (2) : 69 - 72
  • [26] Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma
    Kuribayashi, Hidehiko
    Abe, Shinji
    Kuse, Naoyuki
    Kusunoki, Yuji
    Narato, Ritsuko
    Saito, Hitoshi
    Gemma, Akihiko
    [J]. INTERNATIONAL CANCER CONFERENCE JOURNAL, 2016, 5 (02): : 69 - 72
  • [27] The role of brigatinib in crizotinib-resistant non-small cell lung cancer
    Mezquita, Laura
    Planchard, David
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 123 - 130
  • [28] Expression, purification, and structural studies of phospholamban mutants.
    Ha, KN
    Metcalfe, E
    Zamoon, J
    Veglia, G
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U431 - U431
  • [29] Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R
    Mathi, Gangadhar Rao
    Kang, Chung Hyo
    Lee, Heung Kyoung
    Achary, Raghavendra
    Lee, Ha-Yeon
    Lee, Joo-Youn
    Du Ha, Jae
    Ahn, Sunjoo
    Park, Chi Hoon
    Lee, Chong Ock
    Hwang, Jong Yeon
    Yun, Chang-Soo
    Jung, Hee Jung
    Cho, Sung Yun
    Kim, Hyoung Rae
    Kim, Pilho
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 536 - 549
  • [30] Identification of a novel ALK variant intrinsically resistant to crizotinib
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Soni, Satyajeet
    Jain, Parveen
    Pasricha, Sunil
    Bansal, Abhishek
    Mehta, Anurag
    [J]. CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2020, 2